Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy
Annals of Hematology · 17.04.2026 · 105 (5)
DOI: 10.1007/s00277-026-07009-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 17.04.2026. Verfasst von Tino Vollmer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Hugstetter Straße 55, Freiburg, 79106, Germany.…. Hauptthemen laut MEDLINE: Mediastinal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, B-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Freiburg.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The optimal therapeutic approach for primary mediastinal B-cell lymphoma remains unknown and varies in clinical practice. Dose-adjusted EPOCH-R or R-CHOP-based immuno-chemotherapy with mediastinal radiotherapy are acceptable treatment options. We report a retrospective analysis of PMBL patients treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) consolidation or dose-dense immuno-chemotherapy alone. A comparison of the two consolidation strategies showed no significant difference in 5-year PFS (95.5% vs. 82.4%, HR 0.22 95% CI 0.03–1.69, p = 0.13) or OS (100% vs. 87.1%, HR 0.1 95% CI 0.006–1.69, p = 0.11), with a trend toward better survival in the preplanned HDCT/ASCT group. Notably, 35.3% of patients received additional HDCT/ASCT after an inadequate response to dose-dense immuno-chemotherapy. When comparing all patients, with or without first-line HDCT/ASCT consolidation, regardless of the initial consolidation strategy, we found a significant difference in 5-year PFS (96.2% vs. 75%, HR 0.09 95% CI 0.01–0.83, p = 0.03) and OS (100% vs. 80.1%, HR 0.03 95% CI 0.002–0.7, p = 0.03) for patients treated with HDCT/ASCT. In addition, mediastinal radiotherapy was administered significantly less frequently in patients treated with HDCT/ASCT. In conclusion, high-dose chemotherapy and autologous stem cell transplantation may be a valid strategy to induce a favorable long-term outcome and spare radiotherapy in patients with PMBL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Hugstetter Straße 55, Freiburg, 79106, Germany. tino.vollmer@uniklinik-freiburg.de.
- Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Hugstetter Straße 55, Freiburg, 79106, Germany.
- Institute for Surgical Pathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Kantonsspital Baden, Baden, Switzerland.
Förderung
- Universitätsklinikum Freiburg
Zitieren
APA
Vollmer, T., Strüßmann, T., Glatzki, F., Aumann, K., Fritsch, K., Duyster, J., Mertelsmann, R., Finke, J., & Marks, R. (2026). Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy. Annals of Hematology, 105(5). https://doi.org/10.1007/s00277-026-07009-w
Vancouver
Vollmer T, Strüßmann T, Glatzki F, Aumann K, Fritsch K, Duyster J, et al. Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy. Annals of Hematology. 2026;105(5). doi:10.1007/s00277-026-07009-w
BibTeX
@article{Vollmer2026,
author = {Vollmer, Tino and Strüßmann, Tim and Glatzki, Franziska and Aumann, Konrad and Fritsch, Kristina and Duyster, Justus and Mertelsmann, Roland and Finke, Jürgen and Marks, Reinhard},
title = {Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {5},
doi = {10.1007/s00277-026-07009-w}
}
EUVIMED